Two Sigma Advisers
ZNTL icon

Two Sigma Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Two Sigma Advisers’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,483,500
Closed -$2M – 2217
2025
Q4 		$2M Buy
1,483,500
+22,300
+2% +$32.5K ﹤0.01% 1189
2025
Q3 		$2.21M Buy
1,461,200
+185,286
+15% +$278K ﹤0.01% 1107
2025
Q2 		$1.48M Buy
1,275,914
+433,314
+51% +$571K ﹤0.01% 1259
2025
Q1 		$1.34M Sell
842,600
-47,100
-5% -$102K ﹤0.01% 1331
2024
Q4 		$2.7M Sell
889,700
-259,700
-23% -$851K 0.01% 989
2024
Q3 		$4.23M Buy
1,149,400
+352,500
+44% +$1.28M 0.01% 767
2024
Q2 		$3.26M Buy
796,900
+695,900
+689% +$7.77M 0.01% 950
2024
Q1 		$1.59M Buy
+101,000
New +$1.39M ﹤0.01% 1344
2022
Q4 		– Sell
-22,600
Closed -$490K – 2724
2022
Q3 		$490K Sell
22,600
-32,700
-59% -$894K ﹤0.01% 1850
2022
Q2 		$1.55M Sell
55,300
-13,000
-19% -$344K ﹤0.01% 1350
2022
Q1 		$3.15M Buy
68,300
+1,500
+2% +$80.9K 0.01% 1017
2021
Q4 		$5.62M Sell
66,800
-69,300
-51% -$5.36M 0.01% 714
2021
Q3 		$9.07M Buy
136,100
+81,600
+150% +$4.71M 0.02% 550
2021
Q2 		$2.9M Buy
54,500
+17,500
+47% +$937K 0.01% 1120
2021
Q1 		$1.6M Buy
37,000
+23,900
+182% +$1.03M ﹤0.01% 1383
2020
Q4 		$680K Buy
+13,100
New +$591K ﹤0.01% 1744

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Two Sigma Advisers's ZNTL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 1,483,500 shares — an estimated $2M sold.

Two Sigma Advisers first reported a position in ZNTL in Q4 2020 and held it in 16 quarters. The position peaked at $9.07M in Q3 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Two Sigma Advisers reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,483,500 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $2M.
  • Two Sigma Advisers first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • Two Sigma Advisers's Zentalis Pharmaceuticals position peaked at $9.07M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.